Stable inhibitors of the 5-lipoxygenase pathway for treating Asthma and Cancer
The University of Leipzig has patented a series of Carborane-Based Inhibitors of the 5-LO Lypoxygenase pathway. These inhibitors are selectively cytotoxic towards several leukotriene-dependend melanoma and colon cancer cell lines., while leaving non-malignent cells intact. Furthermore, these inhibitor analogues have shown co-inhibition of heat shock proteins necessary for tumor development in such cell lines. Experimental results on mice showed promising results. Moreover, since these compounds have a high content of boron, they may also be suitable for Boron Neutron Capture Therapy (BNCT), a binary cancer therapy that uses selective boron compounds and thermal neutrons. Furthermore, leukotriene inhibition could be useful in the treatment of asthma, as their production is related to inflammatory responses. The BBZ is looking for organzations interested in acquiring this technology offer, helping perform precilinical and clinical studies, and ultimately leading to the licensing of it.